Photocure fundamentale forhold (PHO)

[TekBot]

Photocure ASA - Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general
meeting on 3 May 2023 at 17:00 hours (CET).

…

Vis børsmeldingen

The minutes from the general meeting setting out the resolved resolutions are
attached hereto.

For further information, please contact:

Photocure

CFO Erik Dahl
Tel: + 47 450 55 000
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure ASA - Correction: Annual general meeting held

Oslo, Norway, 3 May 2023: Photocure ASA (OSE: PHO), held its annual general
meeting on 3 May 2023 at 17:00 hours (CET).

…

Vis børsmeldingen

The minutes (corrected) from the general meeting setting out the resolved
resolutions are attached hereto.

For further information, please contact:

Photocure

CFO Erik Dahl
Tel: + 47 450 55 000
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Photocure ASA: Results for the first quarter of 2023

Oslo, Norway, 10 May 2023 - Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 105.9 million in the first quarter of 2023
(Q1 2022: NOK 81.4 million) and EBITDA of minus NOK 1.2 million (NOK -13.9
…

Vis børsmeldingen

million). Total revenues increased 30% year over year, and 30 high-definition
blue light towers were installed in the first quarter (18 new and 12 upgrades).
Photocure reiterates its guidance for 2023 and expects to deliver new SaphiraT
blue light tower installations in the U.S. in the range of 65 to 75,
consolidated product revenue growth above 20%, and positive EBITDA excluding
business development spending.

“Photocure delivered strong results in the first quarter of 2023, with revenue
in both our North America and European territories rebounding significantly from
the unusually soft fourth quarter last year. Hexvix/Cysview sales increased 30%
year over year driven by higher unit sales, price increases and foreign
exchange. Sequentially, product sales were up 12% from Q4 2022. Typically, the
first quarter is seasonally lower than the preceding fourth quarter, however the
recent pattern is indicative of unusual circumstances,” says Dan Schneider,
President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 106.2 million in the first
quarter of 2023 (NOK 81.6 million), and an EBITDA* of minus NOK 1.2 million (NOK
-13.9 million), driven by a combination of unit growth, price increases and
positive effects of foreign currency exchange. The Hexvix/Cysview revenues ended
at NOK 105.9 million in the quarter (Q1 2022: NOK 81.4 million). The EBIT was
NOK -7.7 million (NOK -19.9 million) and the cash balance at the end of the
period was NOK 246.0 million.

At the end of the first quarter of 2023, the installed base of blue light
cystoscopy (BLC[®]) systems in the U.S. was 388, an increase of 20% or 64 units
since the first quarter of 2022. The installed base in the U.S. includes 69
flexible BLC systems.

“In the U.S., we achieved a record first quarter with each month of Q1 2023
marking a new historic high. The installed base of blue light capital equipment
expanded once again, with 30 new SaphiraT tower installations in Q1 - 18 new
placements and 12 upgrades. Upgrading accounts is a key initiative in 2023, in
addition to new account growth. Importantly, 4 accounts that purchased new high
-definition equipment moved their legacy standard-definition towers to another
location creating additional blue-light enabled facilities. Our flexible BLC
business continued to perform in Q1. Given Karl Storz’s decision to cease
supporting flexible blue light equipment when parts are no longer available, we
will increasingly focus on the rigid cystoscopy segment during the year.
Flexible BLC kit sales represent approximately 5% of our total annual revenue,
and we will work to offset the phase down of blue light surveillance revenue
with kit sales in the surgical segment. Demand for rigid BLC equipment remains
strong, and we continue to expect a record year for new blue light tower
installations in the U.S.,” Schneider adds.

Ongoing healthcare staffing shortages and inflationary pressures leading to
hospital budget tightening, as well as the anticipated phase down of flexible
BLC equipment in the coming quarters present challenges in 2023 for Photocure’s
business. Considering these challenges, Photocure has issued the following
guidance: In 2023, the company expects new SaphiraT blue light tower
installations in the range of 65 to 75, a consolidated product revenue growth
above 20%, and positive EBITDA excluding business development spending.

“Our business is on the upswing with several initiatives to drive growth this
year such as BLC system and image quality upgrades, and new account growth in
North America and in Europe. Other events and activities to watch include the
potential for re-classification of BLC equipment in the U.S., the pursuit of a
solution to develop and commercialize new flexible BLC cystoscopes, and
anticipated Phase 3 results from our partner Asieris for both Hexvix in China
and Cevira later this year. 2023 promises to be an exciting year for Photocure,
and we look forward to executing on our business plan and creating value for our
stakeholders,” Schneider concludes.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
first quarter 2023 financial report on page 23.

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CEST.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20230510_9/

The presentation is scheduled to conclude at 14:45 CEST.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 10 May 2023 at 08:00 CEST.

Kilde

[TekBot]

Photocure ASA - Share option grant

Oslo, Norway, 24 May 2023 - Photocure ASA (the “Company”) (OSE: PHO) has granted
share options to employees.

…

Vis børsmeldingen

A total of 748,000 share options, equal to 2.76% of total shares issued in the
Company, were granted to employees at an exercise price at NOK 59.91. The
exercise price is equal to the weighted average share price 30 trading days
before day of grant with an additional premium of 10% on top of the calculated
average price.

The options are granted in accordance with Photocure’s long term incentive
program and the Company’s guidelines for remuneration of senior executives (the
“Guidelines”), as approved by Photocure’s annual general meeting held 28 April
2022. The share option program and properties of the options are further
described in the Guidelines.

Of the total grant the following was granted to primary insiders:

· Daniel Schneider, President and Chief Executive Officer, 140,000 options.
· Erik Dahl, Chief Financial Officer, 100,000 options.
· Geoffrey Coy, Vice President and General Manager North America, 70,000
options.
· Susanne Strauss, Vice President and General Manager Europe, 70,000 options.
· Anders Neijber, Chief Medical Officer, Global Medical Affairs and Clinical
Development and R&D, 70,000 options.
· David Moskowitz, Head of Investor Relations, 25,000 options.

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (251 likes)

@Rodjer

Det har blitt lagt til et betydelig antall nye klinikker på Cysview ikveld, deriblant 2 Kaisers.

2. @rosk82 (194 likes)

@rosk82

Mnja. Den er i ferd med å flate ut. Men er tydeligvis noen som fremdeles vil selge her nede.

3. @Hayen (172 likes)

@Hayen

Mye god diskusjon her siste dager med endel lange og reflekterte innlegg. Takk for det.

Resten av topp 10:

4. @myk (128 likes)

5. @kreinh (89 likes)

6. @RakiRebSnem (76 likes)

7. @TheLion (59 likes)

8. @Sorlendingen (55 likes)

9. @Meisen (52 likes)

10. @Quadruple (50 likes)

Gratulerer!

[TekBot]

Major shareholder disclosure

See attachment on www.newsweb.no
…

Vis børsmeldingen

Kilde

[Tekspert]

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

1. @Rodjer (249 likes)

@Rodjer

Det har blitt lagt til et betydelig antall nye klinikker på Cysview ikveld, deriblant 2 Kaisers.

2. @rosk82 (135 likes)

@rosk82

Mnja. Den er i ferd med å flate ut. Men er tydeligvis noen som fremdeles vil selge her nede.

3. @myk (106 likes)

@myk

Jeg er redd for at det er en tillits krise til styret i PHO. Når en styreformann og CEO i et selskap går i praksis i null og så at det samme paret skal sitte å styre i et selskap jeg skal investere i da begynner jeg å bli redd for mine investeringer. Jeg spør og hvorfor er det ingen norske investorer i dette selskapet, har det noe med tilliten til styret å gjøre.

Resten av topp 10:

4. @Hayen (100 likes)

5. @kreinh (94 likes)

6. @TheLion (72 likes)

7. @Quadruple (51 likes)

8. @Lucrum (45 likes)

9. @Bebinvest (43 likes)

10. @Rollep (40 likes)

Gratulerer!

[TekBot]

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Press Release - Oslo, Norway, July 6, 2023: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE:
688176) has communicated today that it has completed patient enrollment for the
…

Vis børsmeldingen

Hexvix[®] Phase III bridging trial.

The objective of the multicenter Phase III trial is to support regulatory
approval of Hexvix in Mainland China. The bridging trial is intended to confirm
results from prior clinical trials regarding the safety and detection benefits
of blue light cystoscopy (BLC[®]) with Hexvix compared to white light cystoscopy
in the diagnosis of non-muscle invasive bladder cancer (NMIBC) in a Chinese
population. The clinical trial follows the same protocols for registration
studies in countries where Hexvix already has market authorization.

This study is being led by Peking Union Medical College Hospital and the Chinese
Academy of Medical Sciences. Professor Li Hanzhong, head of the Department of
Surgery at Peking Union Medical College Hospital, is serving as the Principal
Investigator, leading a team of top experts in the field of bladder cancer in
China to carry out this study. Asieris plans to file a new drug application with
the National Medical Products Administration (NMPA) in the future, pending
clinical trial progress and meaningful data.

Asieris Pharmaceuticals is a global biopharma company specializing in
discovering, developing and commercializing innovative drugs for the treatment
of genitourinary tumors and other related diseases.

In January 2021, Asieris entered into a license agreement with Photocure ASA to
obtain the exclusive registration and commercialization rights of Hexvix in
mainland China and Taiwan.
In December 2021, 2021, Hexvix obtained initial clinical use in the Boao Lecheng
International Medical Tourism Pilot Zone in Hainan Province, when the first
patient received blue light cystoscopy with Hexvix at the Hainan General
Hospital. The phase III clinical trial obtained approval from the NMPA in the
first quarter of 2022 and Hexvix was subsequently included in the real-world
clinical data pilot program.

Read Asieris’ full media release here: https://asieris.com/hexvix-a-diagnostic
-drug-for-bladder-cancer-of-asieris-has-completed-the-phase-iii-bridging-trial
-enrollment/

The trial is registered here: https://clinicaltrials.gov/ct2/show/NCT05600322

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 720 000 prevalent cases (5-year prevalence rate)[1a],
573 000 new cases and more than 200 000 deaths in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. https://www.cancer.org/cancer/bladder-cancer.html

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, New Zealand and Israel. Please refer
to Our partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

[Lucrum]

Lenke i børsmeldingen er feil. Riktig link her: Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment - Asieris Pharmaceuticals

« “Completing patient enrollment for the Phase III bridging clinical trial of Hexvix® marks a significant milestone for Asieris Pharmaceuticals.” said Dr. Linda Wu, Chief Development Officer of Asieris,” We are thrilled to have reached this stage in the development of a drug that has the potential to revolutionize the diagnosis of bladder cancer. Our goal is to provide healthcare professionals with a more effective and reliable way for patient with bladder cancer.”»

[Bingo123]

Ikke noe utslag på kursen. Er ikke det rart ?

[myk]

Jo da litt. Dette betyr vel at det nærmer seg godkjenning i China.

[strongbuy]

Dette er jo kjempe nytt!

[myk]

Skulle tro at resultatet er i realiteten også ferdig og at analysedelen er rask.

[TekBot]

Photocure ASA: Invitation to presentation of second quarter and first half year 2023 financial results

Oslo, Norway, 3 August 2023: Photocure ASA (Photocure, PHO: OSE) will announce
the second quarter and first half year 2023 financial results on Wednesday 9
August 2023 at 08:00 CEST and will present a live webcast at 14:00 CEST the same
…

Vis børsmeldingen

day.

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com.

The investor presentation will be streamed live and be hosted by Dan Schneider,
CEO and Erik Dahl, CFO. The presentation will be held in English and questions
can be submitted throughout the event. The presentation is scheduled to conclude
at 14:45 CEST.

The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20230809_1/ (https://eur01.
Error during processing.
ngpage%2Fhegnarmedia%2F20230809_1%2F&data=05%7C01%7CTH%40photocure.no%7C71e8871b5
da24686b67108db634fa6f7%7C0986794f1d6f488980bd853c0715d3c1%7C0%7C0%7C638212965981
131535%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haW
wiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=3O%2B%2FzwigdPTC5eOcQ%2FWhZ%2Fh5L%2BOO%2Bn
LnksvDIusrtxw%3D&reserved=0).

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: ed@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

[TekBot]

Major shareholder disclosure in Photocure ASA

Please see attachment on www.newsweb.no
…

Vis børsmeldingen

Kilde

[TekBot]

Photocure ASA: Results for the second quarter and first half of 2023

Oslo, Norway, 9 August 2023 - Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 115.9 million in the second quarter of 2023
(Q2 2022: NOK 99.9 million), and an EBITDA of NOK 23.4 million (NOK 1.4
…

Vis børsmeldingen

million). The Company reiterates its 2023 annual guidance of new SaphiraT blue
light tower installations in the U.S. expected in the range of 65 to 75,
anticipated consolidated product revenue growth above 20%, and positive EBITDA
excluding business development spending.

“In the second quarter of 2023, Hexvix/Cysview revenue increased 16% year over
year driven by higher unit sales in the U.S., price increases and foreign
exchange. We generated over NOK 23 million in EBITDA, including a positive
contribution from our commercial business and a milestone payment from Asieris
related to the clinical development of Cevira. During the second quarter, we
delivered 4% sequential unit sales growth in North America and 6% in Europe,
demonstrating continued positive traction in the region,” says Dan Schneider,
President & Chief Executive Officer of Photocure.

Photocure reported total group revenues of NOK 144.3 million in the second
quarter of 2023 (NOK 100.6 million), and an EBITDA* of NOK 23.4 million (NOK 1.4
million). Hexvix/Cysview revenues ended at NOK 115.9 million in the quarter (Q2
2022: NOK 99.9 million), and the total group revenues includes a milestone
payment related to the development of Cevira by Asieris of NOK 26.9 million. The
EBIT was NOK 16.8 million (NOK -4.6 million), and the cash balance at the end of
the period was NOK 258.9 million. Photocure paid off the balance of its term
debt during the second quarter of 2023.

At the end of the second quarter of 2023, the total installed base of rigid blue
light cystoscopes (BLC) in the U.S. was 327, an increase of 21% or 56 towers
since the same period in 2022. These figures do not include the 69 flexible
cystoscopy towers that were installed in the U.S. as of December 31, 2022. In
early 2023, Karl Storz announced that it will no longer sell flexible BLC
equipment for use in the surveillance setting and will cease servicing existing
units when the availability of replacement parts has been exhausted, anticipated
in late 2023. Despite Karl Storz’ decision to discontinue its flexible BLC
equipment, surveillance of bladder cancer patients with flexible BLC remains a
strategic priority for Photocure, and the Company plans to pursue initiatives to
restore this specialized equipment in the U.S. and in international markets.

“Offsetting the loss in flexible BLC equipment, the installed base of rigid blue
light capital equipment expanded once again, with 13 new SaphiraT towers
installed in Q2. Eight new placements and five upgrades were installed prior to
Karl Storz’s recent promotional discount program which went into effect in July
and shifted the timing of some tower installations into the third quarter. In
July alone, 40 quotes were issued for new SaphiraT systems, and so far in Q3, 12
purchase orders have been received. We believe that this momentum will result in
a strong second half of the year for new tower placements,” Schneider adds.

Photocure reiterates its guidance for 2023 and continues to expect new SaphiraT
blue light tower installations in the range of 65 to 75, consolidated product
revenue growth above 20%, and positive EBITDA excluding business development
spending.

“I remain confident in Photocure’s future and our ability to bring
Hexvix/Cysview to more patients and establish Blue Light Cystoscopy as standard
of care. The new technology cycle of high-definition blue light equipment from
multiple manufacturers is expected to significantly increase the use of
Hexvix/Cysview. We continue to await information from Karl Storz and the FDA
regarding the Citizen’s Petition to re-classify BLC as a Class 2 device, which
we believe will enable additional equipment manufacturers to enter the U.S.
market and build critical mass behind BLC. Given our prior success in creating
and accelerating the use of BLC in the large untapped bladder cancer
surveillance market, we are pursuing a strategy to reintroduce the technology in
the near to intermediate future. For the remainder of the year, we will focus
on driving sales in the rigid cystoscopy setting, and we look forward to several
milestone events including the anticipated Phase 3 results for Hexvix in China
and Cevira with our partner Asieris,” Schneider concludes.

Photocure also announced today that Jan H. Egberts, M.D. has decided to step
down from his position as Chairperson of the Company’s Board of Directors due to
increased time commitments to his personal companies. Dr. Egberts will leave the
Board in September 2023, and the Nomination Committee has initiated a search for
a new Chairperson.

Robert Blatt, Chair of Photocure’s Nomination Committee, said, “I would like to
express my gratitude to Jan, who has made important contributions to Photocure
during his more than six years as Chairperson of the Board. His dedication and
medical experience will be missed”.

Please find the full financial report and presentation enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
second quarter and first half 2023 financial report on page 23.

The quarterly report and presentation will be published at 08:00 CEST and will
be publicly available at www.photocure.com. Dan Schneider, CEO and Erik Dahl,
CFO, will host a live webcast at 14:00 CEST.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230809_1

The presentation is scheduled to conclude at 14:45 CEST.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.com

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 9 May 2023 at 08:00 CEST.

Kilde

[Chrkni]

“Photocure also announced today that Jan H. Egberts, M.D. has decided to step down from his position as Chairperson of the Company’s Board of Directors due to increased time commitments to his personal companies. Dr. Egberts will leave the Board in September 2023, and the Nomination Committee has initiated a search for a new Chairperson.”

Bull!!!

[myk]

Dette er vel vert minst 10 nok

[Helme5]

Hmmmm, vel ikke helt som forventet (af mig) og næppe helt som ønsket

Hexvix/Cysview revenues in the second quarter of 2023 were NOK 115.9 million (NOK 99.9 million), a 16% increase versus Q2 2022. The sales increase is driven by a combination of price increases and positive effects of foreign currency exchange.

På indtægts siden er stigningen primær valuta og ikke helt den forventede øgede stigning i omsætningen i dette kvartal som vi fik oplyst på Q1 - og hertil skal selvsagt tillægges engangbetalingen fra Asieris på NOK 26.9 million vedrørende Cevira.

Total operating expenses, excluding depreciation and amortization, were NOK 114.0 million (NOK 93.9 million) in the second quarter, mainly due to the impact of foreign exchange.

Stigningen i Total cost var 21 % (altså større end stigning end i omsætningen) - der er lidt skuffende

[rosk82]

Veksten i USA kommer ene og alene fra de rigide skopene nå. De må også dekke inn frafallet som kommer pga. flex. skopene som fases ut.

Så ikke noe stor overraskelse sånn sett. Ble også informert om ved forrige kvartalsrapport. Men Europa bikker snart 70 mil i omsetning…

Annet positive er at man fikk enda en milestone betaling fra Asieris, dette bare underbygger at ting er på gang i Kina. Kan ikke være så mye lenger man kan ignorere Asieris avtalen fra verdivurderingen.